1KDOKI.KDOQI Clinical Prac'tice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease[J].Am J Kidney Dis,2007,49 (Suppl 2):S12-154.
2Rodbard HW,Blonde L,Braithwaite SS,et al.American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus[J].Endocr Pract,2007,13(Suppl 1):1 -68.
3Mancia G,De Backer G,Dominiczak A,et al.2007 Guidelines for the management of arterial hypertension:The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)[J].Eur Heart J,2007,28 (12):1462-1536.
4Rodby RA,Rohde RD,Clarke WR,et al.The Irbesartan type Ⅱ diabetic nephropathy trial:study design and baseline patient charactoristics.For the Collaborative Study Group[J].Nephrol Dial Transplant,2000,15:487-497.
5Brenner BM,Cooper ME,de Zeenw D,et al.Effects of Inesrtan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy[J].N Engl J Med,20010345:861-869.
6Viberti G,Whecldon NM.Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus:a blood pressure-independent effect[J].Circulation,2002,106:672-678.
7Rossing K,Christensen PK,Andersen S,et al.Comparative effects of lrbosartan on ambulatory and office blood pressure:a substudy of ambulatory blood pressure from the lrbesartan in Patients with Type 2 Diabetes and Micreslbuminuria study[J].Diabetes Care,2003,26:569-574.
8Diercks GF,Janssen WM,van Boven AJ,et al.Rationale,design,and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive,nonhypercholesterolemic subjects with microalbuminuria(the Prevention of REnal and Vascular ENdstage Disease Intervention Trial[PREVEND IT])[J].Am J Cardiol,2000,86:635-638.
9Ansquer JC,Fouchor C,Rattier S,et al.Fenofibrate reduces progresaion to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes:results from the Diabetes Atherosclerosis Intervention Study (DAIS).[J] Am J Kidney Dis,2005,45:485-493.
10American Diabetes Association.Standards of Medical Care in Diabetes-2009[J].Diabetes Care,2009,32 (Suppl 1):S13 -61.
6Kim IA,Shin JH,Kim IH,et al. Histone deacetylase inhibitor-me- diated radiosensitization of human cancer ce|ls: class differences and the potential influence of p53 [J]. Clin Cancer Res, 2006,12 (3) :940-949.
7World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Switzerland: Geneva, 1999: 1-4.
8Li Y, Wang S. Glycated albumin up-regulates upstream stimulatory factor 2 gene transcription in mesangial ceils [J]. Am] Physiol Renal Physiol, 2010, 299 (1): F121-127.
9Li Y, Wang S. Glycated albumin activates NADPH oxidasein rat mesangial cells through uwregulation of p47 phox [J]. Biochem Biophys Res Commun, 2010, 397 (1) : 5-11.
